GA-PINDROP
4.5.2022 15:02:13 CEST | Business Wire | Press release
Pindrop , a global leader in voice technology, today announced a new partnership with Google Cloud that will enable it to build and offer new authentication solutions to enhance call center experiences for customers on Google Cloud’s platform. Pindrop will also make its suite of fraud detection and voice security solutions available on Google Cloud Marketplace, as it is now part of the Google Cloud Partner Advantage Program as an Independent Software Vendor (ISV) partner.
Through this partnership, Pindrop plans to offer its call center security and anti-fraud protection solutions with Google Cloud’s Contact Center AI to deliver voice authentication and security solutions that create better experiences for the customer, add security to the call center, and increase flexibility with modern infrastructure. Using Google Cloud’s secure, trusted, and global infrastructure, Pindrop will also be able to deploy new voice security solutions that will give customers the ability to easily automate device-based interactions. Additionally, as a Google Cloud Partner, the two companies will execute a joint go-to-market strategy via Google Cloud Marketplace to augment Pindrop’s products with Google Cloud capabilities in AI, ML, analytics, and more.
“This is another historic moment for Pindrop, and we are thrilled about the partnership with Google Cloud. Together with Google Cloud, we are uniquely positioned to offer customers something genuinely innovative and drive toward our shared vision in the modern contact center world,” said Vijay Balasubramaniyan, CEO and co-founder at Pindrop. “By partnering with Google Cloud, we are truly on the path to delivering on our mission of making technology more human and helping our clients open new worlds by unlocking the power of the human voice.”
“Securing voice-driven call center and support services is a critical requirement for the enterprise technology stack today,” said Nirav Sheth, Director of Partnerships, Google Cloud. “We're thrilled to have innovative technology businesses like Pindrop building on Google Cloud. With Pindrop’s solutions available on Google Cloud Marketplace, organizations will be able to easily deploy Pindrop in their cloud environment and provide AI-enhanced experiences that prioritize secure, satisfactory customer interactions.”
Pindrop helps organizations across financial services, insurance, retail, healthcare, and telecommunications secure voice interactions with passive voice authentication and streamlined automatic number identification (ANI) verification solutions. By deploying Pindrop solutions in their multicloud environments, customers are empowered with the technologies needed to reduce costs associated to fraud loss and increase positive customer care experiences in the call center. A recent Pindrop commissioned Forrester TEI study found that Pindrop customers, who participated in the study, experienced a 10% increase in operational gains for call centers, 15% reduction in fraud incidents and losses, and improved call containment in the IVR by 2% leading to a better experience for customers and employees.
For more information about Pindrop, please visit www.pindrop.com .
About Pindrop
In an increasingly digital world, Pindrop lets people use their voice to seamlessly connect to, enter and unlock new experiences while helping safeguard their privacy. Using its patented voice authentication technology, Pindrop is leading the way to the future of voice by establishing the standard for identity, security, and intelligence for voice interactions. Working with some of the world’s biggest banks, insurers, and retailers, Pindrop enables customers to quickly, conveniently, and securely connect to the information and resources they need. Its voice authentication technology analyzes unique features within the human voice and surrounding audio that enables its customers to prevent fraud and deliver exceptional customer experiences in call centers, when obtaining information from smart devices, and even when activating cars. A privately held company, Pindrop is venture-backed by Andreessen Horowitz, Citi Ventures, Felicis Ventures, CapitalG, GV, IVP, and Vitruvian Partners. Visit pindrop.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005102/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom